US Lumpectomy Market Analysis, Size, and Forecast 2025-2029

US Lumpectomy Market Size 2025-2029 

The lumpectomy market size in US is forecast to increase by USD 1.31 billion at a CAGR of 5.6% between 2024 and 2029.

• The Lumpectomy Market is experiencing significant growth, driven by the increasing incidence of new breast cancer cases and the rising investment by venture capitalists in innovative surgical technologies. However, the high cost of lumpectomy procedures remains a notable challenge for both patients and healthcare providers. Genetic testing is increasingly becoming a part of the diagnostic process. As the demand for minimally invasive and cost-effective surgical options continues to rise, market players are focusing on developing advanced technologies to address these concerns.

• These trends and growth factors are shaping the future of the Lumpectomy Market, making it an intriguing space for investors and industry professionals alike. Explore our comprehensive market trends and analysis report to gain deeper insights into the market's dynamics and future growth prospects. Breast reconstruction and scar management are essential aspects of post-operative care.

What will be the Size of the market During the Forecast Period?

 Request Free Sample

• In the dynamic lumpectomy market, precision medicine and early detection are driving innovation. Patient data management systems enable personalized treatment plans, integrating genetic counseling and liquid biopsy results. Surgical techniques, such as robotic surgery and image-guided surgery, offer minimally invasive options, reducing post-operative complications like scar minimization and skin necrosis. New technologies, including artificial intelligence and machine learning, facilitate accurate diagnosis and improve cosmetic outcomes. Breast cancer research continues to advance, with a focus on breast asymmetry and lymphatic drainage massage for optimal patient care.

• Virtual care and lifestyle modifications are essential components of holistic treatment plans. Healthcare informatics streamlines workflows and enhances communication between healthcare providers. Breast cancer awareness campaigns promote timely intervention, ensuring the best possible outcomes for patients.

• Novel treatments, including aromatase inhibitors, PD-1 inhibitors, and CTL-4 inhibitors, robotics are revolutionizing pain management and hormonal therapy. Stereotactic radiosurgery and intraoperative radiotherapy offer advanced radiotherapy techniques. Immunotherapy agents, targeted therapy, and hormone therapy are integral to personalized medicine. The role of molecular subtypes, tumor grade, and tumor stage in determining survival rate and disease-free survival is well-established. Support groups and clinical trials provide psychological support and facilitate the adoption of adjuvant therapy. Oncoplastic surgery, including skin sparing mastectomy and partial mastectomy, offers improved patient satisfaction.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

• Product
  • Lumpectomy systems
  • Lumpectomy surgical tools
  • Consumables
• End-user
  • ASCs
  • Hospitals
  • Research institutes and academic centers
• Type
  • DCIS
  • Breast cancer stage 1 and stage 2
• Geography
  • North America
    • US

By Product Insights

• The lumpectomy systems segment is estimated to witness significant growth during the forecast period. In the dynamic landscape of breast cancer treatment, companies such as IceCure Medical Ltd. And Endomagnetics Ltd. are leading the way. These key players are dedicated to enhancing clinical outcomes by providing innovative solutions. For instance, ClearCut Medical's ClearSight Magnetic Resonance Imaging (MRI) Systems, an investigational device limited by US Federal law for investigational use only, assists in scanning and distinguishing between cancerous and non-cancerous cells. This technology reduces the need for re-excision cases. The market is witnessing a rise in product approvals, which will propel growth. Companies are focusing on developing markers to improve surgical efficacy, enabling more precise tumor removal. In the realm of breast conservation, radiation therapy plays a crucial role.
• The integration of novel treatments, such as immunotherapy agents, targeted therapy, and hormonal blockers, is transforming the market. Breast imaging and chemotherapy regimens are essential tools in the early detection and treatment of breast cancer. The focus on quality of life and patient satisfaction is a significant trend. The market's evolution is driven by the continuous pursuit of better clinical results and increased adoption of advanced technologies. Companies are investing in research and development to address the unmet needs of patients and healthcare providers. The future holds great promise for the breast cancer treatment market.

Get a glance at the market report of share of various segments Request Free Sample

Market Dynamics

Our US Lumpectomy Market researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of US Lumpectomy Market?

• Growing incidence of new breast cancer cases is the key driver of the market. Breast cancer is a significant health concern in the US, with an estimated 297,790 new cases diagnosed in 2023, including DCIS. The American Cancer Society reports a 13% risk of breast cancer for women in the US. Obesity and hormone replacement therapies are identified as major contributors to the rise in breast cancer cases. Despite this, advancements in breast imaging, targeted therapy, and immunotherapy agents have led to improved disease-free survival rates. The five-year relative survival rate has risen, while breast cancer-related deaths have declined.

• Clinical trials and adjuvant therapy continue to explore new treatments and personalized medicine. Post-operative care, psychological support, and oncoplastic surgery, such as partial mastectomy, are essential components of treatment. Understanding the importance of early detection and ongoing research is crucial in the fight against breast cancer.

What are the market trends shaping the US Lumpectomy Market?

• Rising investment by venture capitalists is the upcoming trend in the market. Lumpectomy market participants, predominantly US-based companies, are dedicated to innovating new treatments and technologies for this procedure. These advancements include novel technologies for tumor localization and pain management. For instance, Cairn Surgical, Inc., raised USD4.5 million in Series A funding in January 2024, which was used to develop their Breast Cancer Locator (BCL) system. This system utilizes 3D-printed guides for improved precision during lumpectomy procedures.

• Moreover, external beam radiotherapy and skin-sparing mastectomy techniques contribute to the market's growth by improving patient outcomes and reducing recovery time. Support groups and ongoing research play a crucial role in increasing awareness and understanding of lumpectomy procedures, further driving market expansion. Besides, advancements in hormonal blockers, such as aromatase inhibitors, and immunotherapies, like PD-1 inhibitors and CTLA-4 inhibitors, are also transforming the lumpectomy landscape. These treatments are essential for managing various molecular subtypes, particularly luminal B, and enhancing quality of life for patients undergoing chemotherapy regimens.

What challenges does US Lumpectomy Market face during the growth?

• High cost of lumpectomy procedure is a key challenge affecting the market growth. Lumpectomy, a common surgical procedure for breast cancer treatment, involves the removal of the tumor while preserving the breast. However, the high cost of lumpectomy procedures is a significant barrier to adoption, with expenses varying based on factors such as hospital choice, cancer stage, and surgeon experience. The average cost for non-cancerous breast lump removal starts at around USD 4000 at top medical facilities. For patients with advanced breast cancer, lumpectomy costs can range from USD 60,637 to USD 134,682 per patient, as determined by insurance coverage.

• These factors contribute to the overall expense of breast cancer treatment, making it crucial for patients and healthcare providers to understand the cost implications and available financial assistance options. Advanced breast cancer treatment incurs significantly higher incremental costs compared to early-stage breast cancer. Neoadjuvant therapy, including anti-HER2 therapies, and subsequent clinical outcomes influence the need for additional treatments such as radiation therapy, breast reconstruction, wound healing, scar management, and stereotactic radiosurgery.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Becton Dickinson and Co. -  The company provides advanced breast tissue marking solutions for open surgical biopsies. 

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Becton Dickinson and Co.
• Carl Zeiss AG
• ClearCut Medical
• Dilon Medical Technologies Inc.
• Endomagnetics Ltd.
• Hologic Inc.
• IceCure Medical Ltd.
• Leica Microsystems
• Merit Medical Systems Inc.
• Novian Health
• Vector Surgical LLC Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Lumpectomy Market In US

• In March 2023, Medtronic plc, a global healthcare solutions company, announced the U.S. Food and Drug Administration (FDA) approval of its Mammotome® System with TumorSelect™ Technology for image-guided breast lumpectomy procedures. This innovative technology enables real-time, intraoperative imaging to improve the accuracy and efficiency of tumor removal (Medtronic Press Release, 2023).
• In October 2024, Ethicon, a part of the Johnson & Johnson Medical Devices Companies, and Merit Medical Systems, Inc. entered into a strategic partnership to co-develop and commercialize a portfolio of innovative surgical devices for minimally invasive procedures, including lumpectomies. This collaboration aims to enhance patient care and expand the reach of both companies in the global surgical market (Ethicon Press Release, 2024).
• In January 2025, Getinge AB, a leading provider of medical technology and solutions, acquired the surgical business of Maquet Holding B.V. & Co. KG. This acquisition strengthened Getinge's position in the surgical market, particularly in the area of lumpectomy procedures, and expanded its product portfolio (Getinge Press Release, 2025).
• In May 2025, the European Commission granted marketing authorization for the Senhance Surgical System, a robotic-assisted surgical platform by TransEnterix, Inc., for performing minimally invasive lumpectomies. This approval marks a significant technological advancement in the field, as the Senhance System uses artificial intelligence and haptic feedback to enhance precision and control during surgical procedures (TransEnterix Press Release, 2025).

Research Analyst Overview

The lumpectomy market continues to evolve as advancements in breast cancer treatment and research unfold. Tumor size, disease-free survival, and clinical outcomes are key factors driving market dynamics. Neoadjuvant therapy, utilizing anti-HER2 therapies, is increasingly being adopted to downsize tumors prior to surgery. Breast imaging technologies, such as stereotactic radiosurgery and novel treatments like aromatase inhibitors and PD-1 inhibitors, contribute to improved clinical outcomes. Radiation therapy, a common post-operative care method, is undergoing advancements with external beam radiotherapy and intraoperative radiotherapy. Hormonal blockers, hormone therapy, and chemotherapy regimens are essential adjuvant therapies, while targeted therapy and immunotherapy agents offer new treatment options.

Breast reconstruction and scar management are crucial aspects of patient care, with skin-sparing mastectomy and tissue expander techniques gaining popularity. Psychological support and quality of life considerations are increasingly integrated into treatment plans. Molecular subtypes, such as Luminal A and B, influence treatment decisions, with genetic testing playing a vital role in personalized medicine. Ongoing clinical trials explore new treatments and techniques, including oncoplastic surgery and partial mastectomy, to enhance patient satisfaction and survival rates. In surgical oncology, tumor grade, tumor stage, and nodal status guide treatment strategies. Wound healing and pain management are essential components of post-operative care.

The market's continuous evolution reflects the ongoing quest for improved patient outcomes and enhanced quality of life.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2025 and 2029
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across US
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch